Linked Life Data

16278416

Source:http://linkedlifedata.com/resource/pubmed/id/16278416

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
21
pubmed:dateCreated
2005-11-9
pubmed:abstractText
Current prostate cancer research in both basic and preclinical trial studies employ genetically engineered mouse models. However, unlike in human prostate cancer patients, rodents have no counterpart of prostatic-specific antigen (PSA) for monitoring prostate cancer initiation and progression. In this study, we established a mouse serum tumor marker from a mouse homologue of human prostate secretory protein of 94 amino acids (PSP94). Immunohistochemistry studies on different histologic grades from both transgenic and knock-in mouse prostate cancer models showed the down-regulation of tissue PSP94 expression (P < 0.001), the same as for PSA and PSP94 in humans. The presence of mouse serum PSP94 was shown by affinity column and immunoprecipitation purification using a polyclonal mouse PSP94 antibody. A competitive ELISA protocol was established to quantify serum PSP94 levels with a sensitivity of 1 ng/mL. Quantified serum levels of mouse PSP94 ranged from 49.84 ng/mL in wild-type mice to 113.86, 400.45, and 930.90 ng/mL in mouse prostatic intraepithelial neoplasia with microinvasion, well differentiated, moderately differentiated, and poorly differentiated prostate cancer genetically engineered prostate cancer mice, respectively (P < 0.01, n = 68). This increase in serum PSP94 is also well correlated with age and tumor weight. Through longitudinal monitoring of serum PSP94 levels of castrated mice (androgen ablation therapy), we found a correlation between responsiveness/refractory prostate tissues and serum PSP94 levels. The utility of mouse serum PSP94 as a marker in hormone therapy was further confirmed by three-dimensional ultrasound imaging. The establishment of the first rodent prostate cancer serum biomarker will greatly facilitate both basic and preclinical research on human prostate cancer.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
1078-0432
pubmed:author
pubmed:issnType
Print
pubmed:day
1
pubmed:volume
11
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
7911-9
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed-meshheading:16278416-Animals, pubmed-meshheading:16278416-Blotting, Western, pubmed-meshheading:16278416-Clinical Trials as Topic, pubmed-meshheading:16278416-DNA, Complementary, pubmed-meshheading:16278416-Disease Models, Animal, pubmed-meshheading:16278416-Down-Regulation, pubmed-meshheading:16278416-Electrophoresis, Polyacrylamide Gel, pubmed-meshheading:16278416-Enzyme-Linked Immunosorbent Assay, pubmed-meshheading:16278416-Gene Expression Regulation, Neoplastic, pubmed-meshheading:16278416-Glycosylation, pubmed-meshheading:16278416-Humans, pubmed-meshheading:16278416-Image Processing, Computer-Assisted, pubmed-meshheading:16278416-Immunohistochemistry, pubmed-meshheading:16278416-Male, pubmed-meshheading:16278416-Mice, pubmed-meshheading:16278416-Mice, Transgenic, pubmed-meshheading:16278416-Prostate-Specific Antigen, pubmed-meshheading:16278416-Prostatic Neoplasms, pubmed-meshheading:16278416-Prostatic Secretory Proteins, pubmed-meshheading:16278416-Recombinant Proteins, pubmed-meshheading:16278416-Time Factors, pubmed-meshheading:16278416-Tumor Markers, Biological
pubmed:year
2005
pubmed:articleTitle
Establishment of a serum tumor marker for preclinical trials of mouse prostate cancer models.
pubmed:affiliation
Department of Surgery, Robarts Research Institute, University of Western Ontario, London, Ontario, Canada.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural